Default Genetics Referrals for Young-Onset Colorectal Cancer

Colorectal Cancer Clinical Trial

Official title:

Pilot Implementation Study of a Default Genetics Referral Process for Patients With Young-Onset Colorectal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05018156
• Other study ID #: 849320
• Status: Completed
• Phase: N/A
• Start date: November 10, 2021
• Est. completion date: August 31, 2022

Study information

• Verified date: December 2022
• Source: University of Pennsylvania
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators will perform a pilot implementation study of a default genetics referral process among patients with young-onset CRC diagnosed between ages 40 and 49.

Description:

The incidence of young-onset colorectal cancer (CRC) - defined as a diagnosis of CRC prior to age 50 - has increased at alarming rates in recent years. Over 75% of cases occur in patients diagnosed between 40-49 years old, a group that is not traditionally included in young adult cancer initiatives tailored only to patients up to 39 years of age. Young age of CRC onset is a defining feature of hereditary CRC syndromes; as such, the National Comprehensive Cancer Network and American College of Medical Genetics and Genomics recommend germline genetics evaluations for all patients diagnosed with CRC under the age of 50. However, multiple studies have shown suboptimal rates and racial and socioeconomic disparities in guideline-recommended genetics evaluations. In this pilot implementation study, the investigators aim to develop, implement, and evaluate the effects of a default genetics referral process among patients with young-onset CRC diagnosed between 40-49 years old. The investigators hypothesize that by applying defaults, or pre-selected choices, to minimize the cognitive effort that patients and clinicians use to make decisions, default referrals will improve rates of genetics referrals while reducing existing racial and socioeconomic disparities. The investigators will implement this intervention at five academic and community hospitals within Penn Medicine that serve a racially, socioeconomically, and geographically diverse patient population. The investigators will use an automated electronic health record-based algorithm to identify eligible patients, after which default referrals for genetic risk evaluation will be made unless patients or their oncology clinicians opt out. The investigators will rigorously evaluate the impact of this default genetics referral process using mixed methods leveraging models and frameworks from the field of implementation science.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 53
• Est. completion date: August 31, 2022
• Est. primary completion date: August 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 49 Years

Eligibility

Inclusion Criteria:

• Newly diagnosed with colon or rectal adenocarcinoma
• Between 40-49 years old at the time of index cancer diagnosis
• At least two visits at Penn Medicine for the evaluation or treatment of the index cancer

Exclusion Criteria:

• Diagnosis of in situ cancer
• Known genetic predisposition to cancer
• Genetic testing after index cancer diagnosis

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Behavioral:
• Default Genetics Referral Process
Patients and their oncology providers will be notified of their eligibility for a cancer genetics referral, with an option to opt out if they are not interested in proceeding. Everyone else will be automatically referred to their local hospital's cancer genetics program for contact and scheduling. Standard genetic counseling, testing, and results disclosure will take place, including usual methods of payment and insurance coverage for testing.

Locations

Country	Name	City	State
United States	Penn Medicine	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Genetics referrals	The number of patients who are ultimately referred to genetics divided by the total number of eligible patients	3 months
Secondary	Scheduled genetics evaluations	The proportion of genetics evaluations that are scheduled divided by the total number of genetics referrals	3 months
Secondary	Completed genetics evaluations	The proportion of genetics evaluations that are completed divided by the total number of scheduled genetics evaluations	3 months
Secondary	Genetic testing	The proportion of genetics evaluations that result in genetic testing divided by the total number of completed genetics evaluations	3 months